What is RenBio?
Established in 2016, RenBio operates at the intersection of advanced immunology and pharmaceutical engineering. The company is primarily focused on the development of best-in-class antiviral antibody therapeutics. By leveraging a next-generation delivery platform, RenBio aims to overcome traditional limitations in antibody administration, providing more efficient and durable treatment options. As a preclinical entity, the firm maintains a lean, high-impact operational model, positioning itself as a critical player in the evolving landscape of infectious disease management and biopharmaceutical innovation.
How much funding has RenBio raised?
RenBio has raised a total of $24.4M across 3 funding rounds:
Debt
$150K
Debt
$264K
Series A
$24M
Debt (2020): $150K with participation from PPP
Debt (2021): $264K led by PPP
Series A (2021): $24M supported by Ruentex Group
Key Investors in RenBio
Ruentex Group
A diversified conglomerate with a strong focus on strategic investments in high-growth sectors including biotechnology and life sciences.
PPP
Public-Private Partnership
What's next for RenBio?
The recent infusion of capital is expected to catalyze the transition of RenBio's lead candidates from preclinical research into more advanced development phases. By prioritizing the optimization of its antibody delivery technology, the company is well-positioned to pursue strategic partnerships or further clinical validation. The focus remains on scaling internal research capabilities and strengthening the intellectual property portfolio, ensuring that RenBio remains at the forefront of the antiviral therapeutic sector as it navigates the complexities of the drug development lifecycle.
See full RenBio company page
